Severity Scores for Cutaneous Lupus Erythematosus
Journal of Investigative Dermatology · 2024-11 · 144 (11) · 2354-2363
DOI: 10.1016/j.jid.2024.07.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2024-11. Verfasst von Tyler B Cepica und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Psychometrics, Quality of Life, Severity of Illness Index. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: NIAMS NIH HHS, Health Services Research and Development, Biomedical Laboratory Research and Development, VA Office of Research and Development.
Abstract (Originalsprache)
Despite the significant disease burden of cutaneous lupus erythematosus (CLE), there have been no United States Food and Drug Administration-approved therapies for 65 years. To facilitate advancement of therapies, severity scores are needed to evaluate QOL, how patients feel, activity of disease, and organ-specific damage to assess response to therapies and disease progression. In this paper, we delineate the development process of provider- and patient-reported severity scores for CLE. Cutaneous Lupus Disease Area and Severity Index (CLASI), a provider-reported measure that distinguishes between activity and damage, has undergone rigorous validation and reliability testing for over 20 years. Its performance has been tested in clinical trials as a primary or secondary endpoint and tool to stratify patients. As an objective disease measure that captures a provider's perspective of disease activity and damage, the CLASI inherently does not assess disease impact on patients' QOL. Cutaneous Lupus Erythematosus Quality of Life (CLEQoL), a patient-reported measure, captures features elucidated through focus groups, including symptoms, emotions, functioning, body image, and photosensitivity. It has undergone psychometric property testing to ensure reliability and validity. Together, CLASI and CLEQoL are simple and reliable CLE-specific severity scores capturing disease activity, damage, and QOL from provider and patient perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: ben.chong@utsouthwestern.edu.
Förderung
- NIAMS NIH HHS
- Health Services Research and Development
- Biomedical Laboratory Research and Development, VA Office of Research and Development
- Department of Veterans Affairs
Zitieren
APA
Cepica, T. B., Gupta, R., Werth, V. P., & Chong, B. F. (2024). Severity Scores for Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 144(11), 2354-2363. https://doi.org/10.1016/j.jid.2024.07.032
Vancouver
Cepica TB, Gupta R, Werth VP, Chong BF. Severity Scores for Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology. 2024;144(11):2354-2363. doi:10.1016/j.jid.2024.07.032
BibTeX
@article{Cepica2024,
author = {Cepica, Tyler B and Gupta, Radhika and Werth, Victoria P and Chong, Benjamin F},
title = {Severity Scores for Cutaneous Lupus Erythematosus},
journal = {Journal of Investigative Dermatology},
year = {2024},
volume = {144},
number = {11},
pages = {2354--2363},
doi = {10.1016/j.jid.2024.07.032}
}
EUVIMED